Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Harvard Stem Cell Institute form CureMN Collaboration to Advance ALS Research

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
Strategic partnership established with the Harvard Stem Cell Institute (“HSCI”) to identify compounds that prevent or slow down the loss of motor neurons.

The collaboration “CureMN” (CureMotorNeuron) will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem (“iPS”) cells that were developed by Dr Lee Rubin, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard, and Dr Kevin Eggan, Early Career Scientist at the Howard Hughes Medical Institute, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard as well as Evotec’s leading drug discovery infrastructure and expertise to identify compounds that will have therapeutic value against this life-threatening disease.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Kevin and Lee have made significant contributions to our understanding of the underlying pathology of motor neuron diseases. Their laboratories have developed a large array of ALS patient-derived motor neuron models that allow screening of diseased human cells in culture – an approach that is sometimes referred to as a ‘clinical trial in a dish’. Our intention is to systematically screen for new mechanisms, targets and compounds that have the potential to be developed into new products that will modify and ideally halt the progression of ALS and potentially other motor neuron diseases.”

“Phenotypic screens based on patient-derived iPS cells are an exciting approach to tackle diseases where tractable mechanisms have remained elusive. Evotec’s proven expertise in high-content screening and deep knowledge in the field of motor neurons is a perfect match for this project. In this latest collaborative effort with Evotec, we look forward to putting our combined dedication and knowledge to work identifying new therapeutics for motor neuron diseases”, added Dr Vivian Berlin, Director Business Development in Harvard’s Office of Technology Development.

This agreement marks the third collaboration between Evotec and leading Harvard Stem Cell Institute scientists – and the fourth with Harvard scientists – and significantly expands a partnership model which combines cutting-edge academic research from Harvard with Evotec’s leading drug platform and expertise. This partnership model efficiently and effectively drives the development of innovative drug candidates.

“This agreement is another important step in our vital collaboration with Evotec, enabling us to hasten the transfer of stem cell-based discoveries to the clinic”, said Brock Reeve, Executive Director of HSCI.

“Evotec, HSCI and Harvard share a commitment to accelerating promising research from the lab to the clinic”, says Isaac T. Kohlberg, Harvard University’s Senior Associate Provost and Chief Technology Development Officer. “Our continued collaboration is based upon a shared vision to match world-class science with industrial capability to address important unmet medical need, which is at the core of our public mission.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Harvard University to Collaborate
The partnership will explore enteroendocrine signals affecting key metabolic pathways.
Thursday, October 10, 2013
Evotec AG: New Hormone to Treat Diabetes Published in “Cell”
Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone “betatrophin” that controls beta cell proliferation as potential diabetes treatment.
Friday, April 26, 2013
Evotec Acquires Compound Management Business from Galapagos
Evotec to further strengthen its integrated innovation offering with world-class compound management.
Thursday, June 02, 2011
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!